| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support development of Adicet's gamma delta T cell therapy gene edited programs
ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced it has signed a strategic platform license (SPL) with Adicet Bio, Inc., a biotechnology company focused on the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
Under the terms of the agreement, Adicet Bio will obtain non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
Adicet Bio has developed a proprietary manufacturing process to activate and expand distinct subsets of gamma delta T cells, enabling scalable production of its off-the-shelf, allogeneic cell therapies for use on demand in the clinical setting. The company's approach combines non-viral gene editing with a robust expansion platform to deliver potent cell therapy products with the potential to treat a broad range of cancers and autoimmune disorders.
Posted In: MXCT
